⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TBPH News
Theravance Biopharma, Inc.
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
prnewswire.com
TBPH
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
globenewswire.com
TBPH
Form 8-K
sec.gov
TBPH
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
prnewswire.com
TBPH
GSK
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
prnewswire.com
TBPH
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
prnewswire.com
TBPH
TBPH ALERT: Levi & Korsinsky Investigates Theravance Biopharma, Inc. for Possible Securities Fraud Violations Ready to Announce with Confidence?
newsfilecorp.com
TBPH
Form 8-K
sec.gov
TBPH
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions
prnewswire.com
TBPH
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
prnewswire.com
TBPH